MEDFORD, N.Y., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received approval for commercial use of its DPP ® Zika IgM/IgG Assay by the Brazilian health regulatory
Robert Passas Ph.D. Appointed President, EMEA and APAC Regions Sharon Klugewicz Appointed President, Americas Region MEDFORD, N.Y., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, announced today
MEDFORD, N.Y., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that the Company has been awarded a $330,000 contract by the U.S. Centers for Disease Control and Prevention (CDC) for
MEDFORD, N.Y., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that the Company has been awarded a grant from the United States Department of Agriculture (USDA) to develop a POC
MEDFORD, N.Y., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution agreement with Isla Lab LLC that includes both Puerto Rico